Single Dose of Psychedelic Reduced Depression Symptoms in Trial

A Phase 2b trial found that a single intranasal dose of mebufotenin benzoate reduced symptoms in adults with treatment-resistant depression, but the research does not establish a new detox method for alcohol, opioids, benzodiazepines, or other substances. The distinction matters because the study involved a monitored psychedelic treatment and, when needed, antidepressant washout under trial protocols.

Published in JAMA on October 26, 2026, the randomized double-blind trial tested two active doses against a low-dose comparator, all alongside psychological support. Its results concern depression care, not withdrawal management or treatment for substance use disorder.

Detox Is Not the Treatment Studied

Medical detox is supervised care for substance withdrawal and stabilization. The JAMA trial instead evaluated mebufotenin for moderate to severe major depressive disorder that had not responded to two to five antidepressant trials during the current episode.

Mebufotenin, also called 5-methoxy-N,N-dimethyltryptamine or 5-MeO-DMT, acts at 5-HT1A and 5-HT2A receptors and is associated with brief psychedelic experiences. The researchers investigated whether its shorter monitoring period could address a practical barrier associated with longer psychedelic sessions.

Nothing in the abstract supports using mebufotenin to manage withdrawal, stop substance use, or replace medication-assisted treatment. People with both depression and substance use concerns need an individual assessment rather than assuming one intervention addresses both conditions.

How the Trial Worked

The study enrolled 193 adults aged 18 to 75 at 38 sites in Australia, Europe, and the United States. It ran between September 2023 and April 2025, with eight weeks of blinded follow-up. The mean participant age was 41, and 59.1% were women.

After antidepressant washout when needed, participants received a single intranasal dose of 8 milligrams, 12 milligrams, or a 0.3-milligram low-dose comparator. The groups comprised 46, 73, and 74 participants, respectively. Psychological support accompanied dosing.

The primary outcome was change on the Montgomery-Asberg Depression Rating Scale from baseline to day 29 for the 12-milligram group versus the comparator. The scale ranges from 0 to 60, with higher scores indicating more severe depression. Researchers also assessed 18 secondary outcomes and evaluated discharge readiness beginning 90 minutes after dosing.

Depression Scores and Discharge Readiness

By day 29, the average depression-score reduction was 11.1 points in the 12-milligram group and 5.5 points in the comparator group. The adjusted mean difference was 5.3 points favoring the active dose. The 8-milligram group had an average reduction of 12.5 points, with a mean difference of 6.2 points versus the comparator.

Day 29 response rates were 35% for 8 milligrams, 34% for 12 milligrams, and 12% for the comparator. Remission rates were 26%, 18%, and 8%, respectively. Both active doses produced significantly greater score reductions than the comparator at other measured points from day 2 through day 57.

Most participants were considered ready for discharge within two hours: 85% in the 8-milligram group and 78% in the 12-milligram group. Discharge readiness in a regulated trial does not mean the medication is approved for general use or suitable for self-administration.

Safety and Study Limitations

The trial was funded by Beckley Psytech Ltd, an AtaiBeckley company, and several authors disclosed employment, consulting, stock, patent, or research relationships involving psychedelic-treatment companies. These disclosures do not negate the results, but they are relevant when evaluating the evidence.

Further research is needed to establish longer-term outcomes, compare the treatment with standard care, and determine its place in clinical practice. The eight-week follow-up cannot establish how long benefits last beyond the study period.

Why Medication Washout Requires Guidance

The trial’s antidepressant washout was part of a controlled research protocol. It should not be copied at home. Starting or stopping antidepressants, opioids, alcohol, or benzodiazepines can create health risks that require clinical review, and alcohol or benzodiazepine withdrawal can be life-threatening without medical supervision.

People searching for local detox programs can ask how a facility evaluates depression and other mental health concerns during intake. Medical detox can address withdrawal, but ongoing depression treatment may need separate coordination after stabilization.

No one should stop a prescribed medication or use a psychedelic substance in an attempt to reproduce this trial. Search Detox.com to find detox centers in your area, or call 800-996-6135Sponsored to speak with a treatment advisor today.